Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Drop in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totalling 19,600 shares, a drop of 7.5% from the May 31st total of 21,200 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 10,200 shares, the short-interest ratio is presently 1.9 days.

Aprea Therapeutics Price Performance

Shares of APRE opened at $3.87 on Thursday. The company has a 50-day moving average of $4.77 and a two-hundred day moving average of $5.49. The stock has a market cap of $21.01 million, a price-to-earnings ratio of -1.17 and a beta of 1.04. Aprea Therapeutics has a one year low of $2.78 and a one year high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.11. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. The firm had revenue of $0.38 million during the quarter. Analysts anticipate that Aprea Therapeutics will post -2.57 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Monday, June 24th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a report on Tuesday, May 14th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.